TEL AVIV - Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), a global pharmaceutical company, announced on Monday that it has reached an agreement with the Israel Tax Authority to resolve all outstanding tax litigation for the years 2008 through 2020. The company will pay a total of $750 million in increments from 2024 to 2029.
This settlement allows Teva to close the chapter on its long-standing tax disputes and continue its focus on patient health and its "Pivot to Growth" strategy. Additionally, the company agreed to additional tax payments of 5%-7% on any future dividends or equity repurchases, with a cap of approximately $500 million in total tax payments.
Teva has confirmed that this settlement will not affect its financial outlook for 2024, which remains consistent with previous forecasts.
With approximately 37,000 employees and operations in 58 countries, Teva is deeply integrated into the Israeli economy and emphasizes its commitment to the state's economic ecosystem.
The settlement terms also stipulate that should Teva distribute dividends or repurchase its equity interests in the future, it will incur an additional tax rate of 5%-7% on the amount of those transactions.
This agreement comes as a significant development for Teva, which has been navigating various challenges in recent years. The company has maintained a strong presence in the pharmaceutical industry, leveraging its experience in generics and increasing its focus on innovative medicine development.
Teva's announcement of the tax agreement is based on a press release statement and provides a clear path for the company to move forward without the overhang of past tax litigation. The settlement underscores Teva's ongoing commitment to its growth strategy and operational focus.
In other recent news, Teva Pharmaceutical Industries has finalized a $750 million settlement with the Israeli Tax Authorities, resolving a tax dispute spanning from 2008 through 2020. The payment, which includes $500 million for corporate taxes and $250 million for other disputed tax issues, will be made over six years, starting in 2024. Additionally, Teva has launched the first generic version of the diabetes drug Victoza, offering a more affordable alternative for patients and healthcare providers.
On the legal front, Teva has initiated an antitrust lawsuit against Corcept Therapeutics (NASDAQ:CORT), alleging the company and Optime Care of maintaining a monopoly over the Korlym market, a treatment for Cushing's syndrome.
Piper Sandler and Barclays (LON:BARC) have both maintained an Overweight rating on Teva shares, with Piper Sandler's optimism based on positive views on TEV-749, Teva's long-acting antipsychotic medication, and Barclays expecting at least a $50 million increase in Teva's top-line revenue due to the performance of Simlandi.
Teva is also implicated in opioid crisis settlements which now exceed $46 billion. These settlements result from lawsuits accusing pharmaceutical manufacturers, including Teva, of contributing to the opioid addiction epidemic.
Lastly, Teva has appointed Matthew Shields as the Executive Vice President of Teva Global Operations, bringing over 25 years of experience in the biopharmaceutical and animal health industries to his new role. These are the recent developments involving Teva Pharmaceuticals.
InvestingPro Insights
As Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) settles its tax disputes and looks toward a future of growth, key financial metrics and analyst insights from InvestingPro provide a nuanced view of the company's current standing and potential trajectory.
InvestingPro Data shows that Teva's market capitalization stands at a robust $18.73 billion, underscoring its significant presence in the pharmaceutical industry. Despite a negative P/E ratio over the last twelve months, signaling that the company was not profitable during that period, analysts have a positive outlook, with expectations of a turnaround to profitability this year. This shift is reflected in the adjusted P/E ratio for the last twelve months as of Q1 2024, which is a more favorable 16.65.
The company's revenue growth remains solid, with a 7.23% increase over the last twelve months as of Q1 2024. This growth is complemented by a strong gross profit margin of 48.96%, indicating Teva's ability to maintain profitability in its core operations.
InvestingPro Tips highlight that Teva is a prominent player in the Pharmaceuticals industry and has demonstrated a high return over the last year, with a 116.4% price total return. This impressive performance is coupled with the fact that the stock is trading near its 52-week high, at 93.22% of this mark.
However, it is important to note that three analysts have revised their earnings estimates downwards for the upcoming period, which may be a point of consideration for investors. Additionally, Teva's short-term obligations currently exceed its liquid assets, indicating potential liquidity concerns that should be monitored.
InvestingPro offers additional insights into Teva's financial health and future prospects, with more tips available at https://www.investing.com/pro/TEVA. For readers looking to delve deeper, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and gain access to a total of 11 InvestingPro Tips that provide a comprehensive analysis of Teva's performance and outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.